Opicinumab: is it a potential treatment for multiple sclerosis?

Zubair Ahmed; Daniel Fulton; Michael Douglas

doi:10.21037/atm.2020.03.131

Opicinumab: is it a potential treatment for multiple sclerosis?

Zubair Ahmed, Daniel Fulton, Michael Douglas

Inflammation and Ageing

Research output: Contribution to journal › Editorial › peer-review

221 Downloads (Pure)

Abstract

Cadavid et al. (1) reported the results of the SYNERGY trial using opicinumab, which is a fully humanised antiLINGO-1 antibody in multiple sclerosis (MS) patients.The study evaluated the clinical safety, efficacy, and pharmacokinetics of four different doses of opicinumab versus placebo added on to intramuscular interferon-β1a over 72 weeks in patients with relapsing MS. However, the findings of the clinical trial did not show a significant doselinear improvement in disability compared with placebo in patients with relapsing MS.

Original language	English
Journal	Annals of Translational Medicine
Early online date	5 Mar 2020
DOIs	https://doi.org/10.21037/atm.2020.03.131
Publication status	E-pub ahead of print - 5 Mar 2020

Access to Document

10.21037/atm.2020.03.131

Ahmed_et_al_Opicinumab_Annals_of_Translational_Medicine_2020Final published version, 141 KBLicence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

http://atm.amegroups.com/article/view/38872Licence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Cite this

@article{50c03759700a44b18cc01fee6aa21a4f,

title = "Opicinumab: is it a potential treatment for multiple sclerosis?",

abstract = "Cadavid et al. (1) reported the results of the SYNERGY trial using opicinumab, which is a fully humanised antiLINGO-1 antibody in multiple sclerosis (MS) patients.The study evaluated the clinical safety, efficacy, and pharmacokinetics of four different doses of opicinumab versus placebo added on to intramuscular interferon-β1a over 72 weeks in patients with relapsing MS. However, the findings of the clinical trial did not show a significant doselinear improvement in disability compared with placebo in patients with relapsing MS. ",

author = "Zubair Ahmed and Daniel Fulton and Michael Douglas",

year = "2020",

month = mar,

day = "5",

doi = "10.21037/atm.2020.03.131",

language = "English",

journal = "Annals of Translational Medicine",

}

TY - JOUR

T1 - Opicinumab

T2 - is it a potential treatment for multiple sclerosis?

AU - Ahmed, Zubair

AU - Fulton, Daniel

AU - Douglas, Michael

PY - 2020/3/5

Y1 - 2020/3/5

N2 - Cadavid et al. (1) reported the results of the SYNERGY trial using opicinumab, which is a fully humanised antiLINGO-1 antibody in multiple sclerosis (MS) patients.The study evaluated the clinical safety, efficacy, and pharmacokinetics of four different doses of opicinumab versus placebo added on to intramuscular interferon-β1a over 72 weeks in patients with relapsing MS. However, the findings of the clinical trial did not show a significant doselinear improvement in disability compared with placebo in patients with relapsing MS.

AB - Cadavid et al. (1) reported the results of the SYNERGY trial using opicinumab, which is a fully humanised antiLINGO-1 antibody in multiple sclerosis (MS) patients.The study evaluated the clinical safety, efficacy, and pharmacokinetics of four different doses of opicinumab versus placebo added on to intramuscular interferon-β1a over 72 weeks in patients with relapsing MS. However, the findings of the clinical trial did not show a significant doselinear improvement in disability compared with placebo in patients with relapsing MS.

U2 - 10.21037/atm.2020.03.131

DO - 10.21037/atm.2020.03.131

M3 - Editorial

JO - Annals of Translational Medicine

JF - Annals of Translational Medicine

ER -

Opicinumab: is it a potential treatment for multiple sclerosis?

Abstract

Access to Document

Fingerprint

Cite this